196 related articles for article (PubMed ID: 26878155)
1. Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.
Tomita Y; Karapetis CS; Ullah S; Townsend AR; Roder D; Beeke C; Roy AC; Padbury R; Price TJ
Acta Oncol; 2016; 55(4):480-5. PubMed ID: 26878155
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.
Hurwitz HI; Bekaii-Saab TS; Bendell JC; Cohn AL; Kozloff M; Roach N; Mun Y; Fish S; Flick ED; Grothey A;
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):323-32. PubMed ID: 24686090
[TBL] [Abstract][Full Text] [Related]
3. The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.
Hammerman A; Greenberg-Dotan S; Battat E; Feldhamer I; Bitterman H; Brenner B
Acta Oncol; 2015 Feb; 54(2):164-70. PubMed ID: 25350524
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
[TBL] [Abstract][Full Text] [Related]
5. A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer.
Kumar R; Jain K; Beeke C; Price TJ; Townsend AR; Padbury R; Roder D; Young GP; Richards A; Karapetis CS
Cancer; 2013 Feb; 119(4):722-8. PubMed ID: 22990939
[TBL] [Abstract][Full Text] [Related]
6. Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.
Aljehani MA; Morgan JW; Guthrie LA; Jabo B; Ramadan M; Bahjri K; Lum SS; Selleck M; Reeves ME; Garberoglio C; Senthil M
JAMA Surg; 2018 Jan; 153(1):60-67. PubMed ID: 28975237
[TBL] [Abstract][Full Text] [Related]
7. Comparable survival outcome of metastatic colorectal cancer in Indigenous and non-Indigenous patients: Retrospective analysis of the South Australian metastatic colorectal cancer registry.
Tomita Y; Karapetis CS; Roder D; Beeke C; Hocking C; Roy AC; Townsend AR; Padbury R; Maddern G; Price TJ
Aust J Rural Health; 2016 Apr; 24(2):85-91. PubMed ID: 26255652
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA.
Franchi M; Barni S; Tagliabue G; Ricci P; Mazzucco W; Tumino R; Caputo A; Corrao G;
Oncologist; 2019 Mar; 24(3):358-365. PubMed ID: 30097524
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
10. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy plus bevacizumab versus chemotherapy plus cetuximab as first-line treatment for patients with metastatic colorectal cancer: Results of a registry-based cohort analysis.
Bai L; Wang F; Li ZZ; Ren C; Zhang DS; Zhao Q; Lu YX; Wang DS; Ju HQ; Qiu MZ; Wang ZQ; Wang FH; Xu RH
Medicine (Baltimore); 2016 Dec; 95(51):e4531. PubMed ID: 28002313
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
Stein A; Petersen V; Schulze M; Seraphin J; Hoeffkes HG; Valdix AR; Schroeder J; Herrenberger J; Boxberger F; Leutgeb B; Hinke A; Kutscheidt A; Arnold D
Acta Oncol; 2015 Feb; 54(2):171-8. PubMed ID: 25307517
[TBL] [Abstract][Full Text] [Related]
13. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
Renouf DJ; Lim HJ; Speers C; Villa D; Gill S; Blanke CD; O'Reilly SE; Kennecke H
Clin Colorectal Cancer; 2011 Jun; 10(2):97-101. PubMed ID: 21859560
[TBL] [Abstract][Full Text] [Related]
14. Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.
Jordan F; Grundmann N; Schenkirsch G; Märkl B; Messmann H; Anthuber M; Schmid C; Trepel M
Anticancer Res; 2018 Sep; 38(9):5539-5546. PubMed ID: 30194214
[TBL] [Abstract][Full Text] [Related]
15. The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study.
Lee B; Wong HL; Tacey M; Tie J; Wong R; Lee M; Nott L; Shapiro J; Jennens R; Turner N; Tran B; Ananda S; Yip D; Richardson G; Parente P; Lim L; Stefanou G; Burge M; Iddawela M; Power J; Gibbs P
Asia Pac J Clin Oncol; 2017 Aug; 13(4):314-321. PubMed ID: 27885818
[TBL] [Abstract][Full Text] [Related]
16. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
Kabbinavar FF; Hurwitz HI; Yi J; Sarkar S; Rosen O
J Clin Oncol; 2009 Jan; 27(2):199-205. PubMed ID: 19064978
[TBL] [Abstract][Full Text] [Related]
17. Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer.
Wong HL; Lee B; Field K; Lomax A; Tacey M; Shapiro J; McKendrick J; Zimet A; Yip D; Nott L; Jennens R; Richardson G; Tie J; Kosmider S; Parente P; Lim L; Cooray P; Tran B; Desai J; Wong R; Gibbs P
Clin Colorectal Cancer; 2016 Jun; 15(2):e9-e15. PubMed ID: 26968236
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
19. BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?
Price TJ; Beeke C; Townsend AR; Lo L; Amitesh R; Padbury R; Roder D; Maddern G; Moore J; Karapetis C
Mol Diagn Ther; 2016 Feb; 20(1):75-82. PubMed ID: 26714964
[TBL] [Abstract][Full Text] [Related]
20. Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology.
Cartwright TH; Yim YM; Yu E; Chung H; Halm M; Forsyth M
Clin Colorectal Cancer; 2012 Dec; 11(4):238-46. PubMed ID: 22658457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
